ifinatamab deruxtecan
mAbexperimentalADC
Clinical trial activity
12 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
6
Phase 2
12
Phase 3
2
Phase 4
0
Earliest trial started Oct 17, 2019 (NCT04145622)
Timeline
Indications
Mechanism of action
- CD276 antigenINHIBITOR
CD276 inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
- Payload
- deruxtecan
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5095331 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07227597 | Phase 1/Phase 2 (Phase 2) | Dec 12, 2025 | Daiichi Sankyo, Merck |
| NCT06863272 | Phase 1/Phase 2 (Phase 2) | Jun 17, 2025 | Daiichi Sankyo, Merck |
| NCT06780098 | Phase 2 | May 23, 2025 | Daiichi Sankyo, Merck |
| NCT06780085 | Phase 2 | May 13, 2025 | Daiichi Sankyo, Merck |
| NCT06925737 | Phase 3 | May 13, 2025 | Daiichi Sankyo, Merck |
| NCT06780111 | Phase 1/Phase 2 (Phase 2) | Apr 23, 2025 | Daiichi Sankyo, Merck |
| NCT06780137 | Phase 1/Phase 2 (Phase 2) | Mar 1, 2025 | Daiichi Sankyo, Merck |
| NCT06644781 | Phase 3 | Feb 28, 2025 | Daiichi Sankyo, Merck |
| NCT06362252 | Phase 1/Phase 2 (Phase 2) | Jul 22, 2024 | Daiichi Sankyo, Merck |
| NCT06330064 | Phase 2 | Apr 10, 2024 | Daiichi Sankyo, Merck |
| NCT05280470 | Phase 2 | Jun 17, 2022 | Daiichi Sankyo |
| NCT04145622 | Phase 1/Phase 2 (Phase 2) | Oct 17, 2019 | Daiichi Sankyo |
Showing 12 of 12 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Daiichi Sankyo | For profit | 12 | 5 | 2 | 2019 |
| Merck | For profit | 10 | 7 | 2 | 2024 |
2 organizations
Page 1 / 1